
In expanded studies, Early Prostate Cancer Antigen-2 (EPCA-2) continues to demonstrate high specificity and sensitivity as a serum biomarker for prostate cancer, reported the researchers from the Johns Hopkins University School of Medicine, Baltimore, who developed this diagnostic tool.